Life support system for children with Cystic Fibrosis
Problem statement
To move forward on the Life Support System development, we must attract, develop and retain the best scientific minded talent on: electronics, mechatronics, mechanics & programing.
Helping patients with acute respiratory failure to breath:
Cystic fibrosis is one the most common genetic disorders that causes among other illness, difficulty to breathe. It affects more than 30,000 children in USA and there is no cure yet. More than 70,000 world wide. (Cystic Fibrosis Foundation)
Lung cancer affects more than 130,000 patients in USA and life expectancy is severely reduced due lung failure. It is the main cause of death among cancers in the world representing 1.44 million cases worldwide. (World Cancer Research Fund)
Pneumonia is an infection that inflames the air sacs in one or both lungs. It accounts for 14% of all deaths of children under 5 years old, killing 740 180 children in 2019 (WHO, 2019)
Severe COVID. Pandemic has proven the great vulnerability on the Intensive Care Units. Mechanical ventilators will help but only as long as there still be a functioning part of lung tissue. Beyond that, patient’s prognosis will be severe detrimental.
A life support system which works like an artificial lung device would bring a glimpse of hope to increase the patients’ prognosis for all severe diseases.
Regarding our community situation, we must attract, develop and retain the best talent
Drug cartels are taking the toll. Extreme violence has made scientific talent minded students to flee away in pursuit of a career path development.
We believe that by promoting high complexity tech projects on the region, we can revert this migration trend and bring back the talent as a way to improve local competitiveness and combat social degradation due violence with SCIENCE.
By doing so, we will accelerate the Technology Readiness Level to reduce the Life Support System’s Time to Market.
Thanks to the King Baudouin Foundation through the Ernest Solvay Fund we are ready for a good start. However, with the MIT Challenges synergy we will be able to incentive young scientific talented students and ensure rigorous technical assessment that will help them to develop a solid career path.
“For Solve Use Only.”
What it is?
Our solution is a Life Support System for patients with acute respiratory failure: Cystic Fibrosis, Lung Cancer, Pneumonia, COVID and EPOCs.
What does it do?
It completely replaces the pulmonary function named “Hematosis” consisting on the interchange of oxygen from the venous blood.
In simple terms, it helps people to breathe without employing their lungs.
Feel free to review photographic evidence at the Project SHEA Life support system folder in the next link. We would like to remind that due the confidentiality the project requires all the information of the link remains confidential and is “For Solve Use Only”. It should not be used on any public setting.
At the that you can find at the next link:
Main statement
We will serve patients with acute respiratory failure by increasing the Technology Readiness Level of our device. In doing so, we will attract, develop and retain scientific minded students and professionals to accelerate the Time to Market.
Regarding the device development
Cystic fibrosis is one the most common genetic disorders that causes among other illness, difficulty to breathe. It affects more than 30,000 children in USA and there is no cure yet. More than 70,000 worldwide. (Cystic Fibrosis Foundation)
Lung cancer affects more than 130,000 patients in USA and life expectancy is severely reduced due lung failure. It is the main cause of death among cancers in the world representing 1.44 million cases worldwide. (World Cancer Research Fund)
Pneumonia is an infection that inflames the air sacs in one or both lungs. It accounts for 14% of all deaths of children under 5 years old, killing 740 180 children in 2019 (WHO, 2019)
Severe COVID. Pandemic has proven the great vulnerability on the Intensive Care Units. Mechanical ventilators will help but as long as there still be a functioning lung. Beyond that patient’s prognosis is severe detrimental.
An artificial lung device would bring a glimpse of hope to increase favorable the patients prognosis for all these serve diseases.
Regarding our community
Drug cartels are taking the toll. Extreme violence has made scientific talent minded students to flee away in pursuit of a career path development.
We believe that by promoting high complexity tech projects on the region, we can revert this migration trend and bring back the talent as a way to improve local competitiveness and combat social degradation due violence with SCIENCE.
“For Solve Use Only.”
Regarding our project
Our team is conformed with leaders on the specific areas from engineering like electronics, mechatronics, systems, etc; to clinical/medical doctors like internal medicine, hematology, pnuemology.
By having a strong medical doctor’s team, we have had close access to the needs, challenges and suffering from acute respiratory failure patients.
Regarding our community
Narco violence in our community has truncated the professional career development from scientific minded students whom had fled due the excessive violence.
Thanks to the King Baudouing Fundation Support we will bring back those students and by promoting high tech complex project we will open a professional development path.
We are confident that by helping them we will be helping us, students will engage with initiatives, will commit with community needs and will tackle world’s biggest challenges.
Feel free to review photographic evidence at the Project SHEA Life support system folder, the External Consultancy Science & Technology National Council, the Universities Collaborations folder & the 5. Promoting Science among students folder in the next link where it shows our commitment with the community. We would like to remind that due the confidentiality the project requires all the information of the link remains confidential and is “For Solve Use Only”. It should not be used on any public setting.
At the that you can find at the next link:
https://home.mycloud.com/actio...
- Optimize holistic care for people with rare diseases—including physical, mental, social, and legal support
- Support daily care management for patients and/or their caregivers
- Pilot
We want to join this challenge, because the MIT has the technical capabilities (like topics of artificial intelligence) that could help us to enhance ours and build a strong synergy.
Because we have the will, the talent and the technology to save lives and make an everlasting impact for many patients around the world who are suffering from acute respiratory failure.
Moreover, we can give some more tool to overcome their illness.
This is not just a technology, is a way to bring hope many people in need.
Cultural barriers
Sourcing scientific minded talent is difficult due its scarcity. As a countermeasure we are developing a NGO focused on attracting, developing and impulse regional scientific minded students. Recently we have been awarded by the King Baudouin Foundation through the Ernest Solvay fund to boost local and regional scientific minded talent.
Financial barriers
Mexican geopolitical scenario has limited the availability of financial resources for scientific and research activities. We are overcoming this barrier by executing an international funding strategy. Setting up an office in USA would allow us to apply to a great set of funding opportunities.
Talent barriers
We would like, with the support from the Challenge to link high talented USA students with high talented Mexico students as a way to stimulate the professionals and enhance the reach of our talent development initiative.
“For Solve Use Only.”
Our device provides a life support service for patients with degenerative or acute respiratory failure.
Our innovation allows a high blood flow while reducing the clot formation risk that could derive on a thrombosis as side effect.
Our main focus are children with Cystic Fibrosis due its life spam is considerably reduced due the illness. Same case for lung cancer patients that succumb primarily by the lung capacity degradation.
There are no high blood flow respiratory support systems on the market that can be used in the long term.
We expect it to be a disruptive solution among the existing devices on the market due its high blood flow and clot formation prevention.
Feel free to review photographic evidence at the Project SHEA Life support system folder in the next link where it shows our commitment with the community. We would like to remind that due the confidentiality the project requires all the information of the link remains confidential and is “For Solve Use Only”. It should not be used on any public setting.
At the that you can find at the next link:
https://home.mycloud.com/actio...
Next year:
- We aim to conform an ethics committee to prepare a protocol for test on humans as a requirement for the humans’ trial FDA approval.
- To have successfully performed the animal trials test.
- To enhance our facilities for next stages of testing.
Next five years:
- We aim to be already deploying our service, in Latin America, USA, UK, Europe and Australia.
“For Solve Use Only.”
There are many factors we are considering in order to properly asses our progress and achieve our goals.
The technology indicator:
The measurement is based on the Technology Readiness Level developed by the NASA.
The finance indicator:
It is based on the amount on funding we are securing.
So far we have been granted with $287,765 USD in funding from the King Baudouin Foundation through the Ernest Solvay Fund, the National Entrepreneur Fund and the Science & Technology National Council.
Feel free to review evidence at the 0. Previous funding folder in the next link. We would like to remind that due the confidentiality the project requires all the information of the link remains confidential and is “For Solve Use Only”. It should not be used on any public setting.
At the that you can find at the next link:
https://home.mycloud.com/actio...
Synergies indicator:
It is based on the number of institutions internationally with whom we have signed a collaboration agreement.
Talent reach indicator:
It is based on the number of talented, scientific minded students and/or professionals we are able to reach.
All these indicators are based on a strategy for securing proper execution which is based on the Balanced Score Card.
Our activities are guided by the NASA Scale for assessing the Technology Readiness Level for a new technological development.
The main problem for children with Cystic Fibrosis, patients with lung cancer, pneumonia and COVID-19 has been not the disease itself but the progressive or acute respiratory failure from the lungs. A lung transplant is complicated, prohibitively expensive and most of the times unavailable.
Having a device that could support the lung function in the long term to an affordable cost is a remarkable improvement in the prognosis and life expectancy for the patients with progressive or acute respiratory failure.
The potential of patients to serve come from the 30,000 children with Cystic Fibrosis and 130,000 with lung cancer alone in the USA; however, there are 70,000 ill children and 1.44 million patients respectively, worldwide.
What would you do if you knew you have the capabilities to improve the life of at least 160,000 people in USA?
“For Solve Use Only.”
To properly address this question we must first make it clear what we are aiming to achieve.
An artificial lung replacement device is not an easy project. It is full of many complexities that go through many fields from the medical like hemodynamics, pneumology, cardiology, intensivism, critical medicine, urgenciology, to technical fields like biomedics, electronics, mechatronics, mechanics, systems.
This multidisciplinary project must properly choreograph the input signals from the instrumented sensors to filter in order to be converted to a digital signal that a microprocessor will analyze.
Once the acquired signal is in the secondary microprocessors, it is sent to the main control board so it can be evaluated to take the appropriate control action accordingly with its PID gain selected algorithm.
So far, we have talked about instrumentation, electronics, systems and control, however this is just a small part of the whole system.
There are many other areas to focus like the vital signs monitor, the out of range oximeters configuration, the oxygen sensors and calibrations that will be more in the area of biomedics.
Added to this, the clinical aspects also must be considered and translated to their equivalent electro o thermodynamic parameters.
With the implementation of all the previous cited parameters, now we can begin to control the biochemical phenomena.
As you may realize it is hard to describe the specifics about this topic while trying to preserve the technology confidentiality, so we will share with you some basic photos (not to be published on website) and “For Solve Use Only.” At the Project SHEA Life support system folder that you can find at the next link:
- A new technology
- Biotechnology / Bioengineering
- Imaging and Sensor Technology
- 3. Good Health and Well-being
- 9. Industry, Innovation, and Infrastructure
- Mexico
- Mexico
- United States
- Hybrid of for-profit and nonprofit
We are against people being labelled in any way. We are people! We are all the same!
We select our team in terms of their moral values, their capabilities, and their commitment.
“For Solve Use Only.”
Value proposition:
Our value proposition consists on a service for monitoring vital signs and providing a life support system for Intensive Care Unit patients with acute respiratory failure at a reduced cost.
Insurance companies will require it as it will reduce the cost of ICU care and will provide an additional coverture from which they may profit.
Segments (key customers and beneficiaries):
In USA alone Cystic Fibrosis affect more than 30,000 children with a median survival age of 14.2 years.
Lung Cancer is one of the deadliest cancers accounting for more than 130,000 deaths a year in USA alone.
Pneumonia, EPOCs, Covid-19, all of them may degenerate to cause acute respiratory failure.
By succeeding on developing a life support system for acute respiratory failure Cystic Fibrosis children survival age may be increased; lung cancer patients can improve its overlife, pneumonica & COVID-19 patients’ prognosis can be greatly improved, saving lifes.
Channels
There are two main channel for service distribution. The private channel service will be provided through contracts with insurance companies or directly with large private hospitals. The public channel service will be provided on high specialization public hospitals.
Intervention
Consist on an Intensive Care Unit Service.
Key activities
Securing availability of devices. Training proper use. Providing maintenance. Procuring sterilization for components. Monitoring performance. Disposal of used supplies.
Key resources
Procuring 24/7 technical support. Securing sufficient stock of replacement materials.
Partners
Hospitals and medical personnel, insurances, suppliers.
Revenue
Device availability fixed revenue. Device rent, supplies consumption.
Cost structure
Preventive and corrective maintenance. Technicians, physicians training. Procurement logistics and machine distribution. Overheads. Supplies manufacturing.
- Organizations (B2B)
“For Solve Use Only.”
At this stage:
To reach the development of these devices we have been awarded with $287,765 USD in funding from the King Baudouin Foundation through the Ernest Solvay Fund, the National Entrepreneur Fund and the Science & Technology National Council.
Feel free to review evidence at the 0. Previous funding folder in the next link. We would like to remind that due the confidentiality the project requires all the information of the link remains confidential and is “For Solve Use Only”. It should not be used on any public setting.
At the that you can find at the next link:
https://home.mycloud.com/actio...
The backup from these institutions are allowing us to increase our international institutional and talent reach which will accelerate our funding securing objectives.
On subsequent stages:
Main channel of revenue will come from capital investors.
Maturity stage:
Once the technology has reached its maturity, the revenue streams will come from the private sector through contracts with multinational insurance companies; and to from the public sector, through public health contracts with federal governments to serve high specialization hospitals.
“For Solve Use Only.”
At this stage:
To reach the development of these devices we have been awarded with $287,765 USD in funding from the King Baudouin Foundation through the Ernest Solvay Fund, the National Entrepreneur Fund and the Science & Technology National Council.
Feel free to review evidence at the 0. Previous funding folder & King Baudouin folder, in the next link. We would like to remind that due the confidentiality the project requires all the information of the link remains confidential and is “For Solve Use Only”. It should not be used on any public setting.
At the that you can find at the next link:
https://home.mycloud.com/actio...
At the next stage:
Once the device has reached enough TRL maturity our focus will move to secure capital investment, internationalization and high medical/tech talent through seed capital, equity interchange etc.
We are being advised by Abeona Capital and began conversations with the Wellcome Fund a specialized UK fund for bioengineering research.
This funding will allow us to begin human trials.
Finally, at the third stage:
We will be advised by the previous incorporated funds to reach mayor investment firms, request FDA and EMA approval for market growth in North America and Europe.